lasmecabtagene timgedleucel
Generic: Lasmecabtagene Timgedleucel
lasmecabtagene timgedleucel: 1 clinical trial tracked.
lasmecabtagene timgedleucel evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about lasmecabtagene timgedleucel, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (1)
Open Label Dose-escalation and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART22 (Allogeneic Engineered T-cells Expressing Anti-CD22 Chimeric Antigen Receptor) in Patients With Relapsed or refractoryCD22+ B-cell Acute Lymphoblastic Leukemia (B-ALL)
Primary endpoint: Incidence of AE/SAE/DLT [Safety and Tolerability]
Interventionalopen52 targetStarted 2019-10Completion 2026-0619 sites · France, United StatesCellectis S.A.